Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.247
Neutral
RSI(14)
47.715
Neutral
STOCH(KDJ)(9,3,3)
22.267
Buy
ATR(14)
0.884
Low Volatility
CCI(14)
-100.678
Sell
Williams %R
78.407
Sell
TRIX(12,20)
0.103
Sell
StochRSI(14)
81.343
Buy
Amarin Corporation PLC
AMRN14.750USD
+0.660+4.68%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
306.77MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Amarin Corporation PLC
Currency: USD Updated: 2026-02-06Key Insights
Amarin Corporation PLC's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 112 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 12.00.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Amarin Corporation PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Amarin Corporation PLC Highlights
StrengthsRisks
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Overvalued
The company’s latest PE is -3.53, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 4.18M shares, increasing 0.10% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 0.00 shares of this stock.
Analyst Rating
Based on
2
analysts
Hold
Current Rating
12.000
Target Price
-14.83%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Amarin Corporation PLC is 8.67, ranking 34 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 49.67M, representing a year-over-year increase of 17.43%, while its net profit experienced a year-over-year increase of 69.21%.
Score
Financials
7.41
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.85
Operational Efficiency
10.00
Growth Potential
9.52
Shareholder Returns
7.58
Amarin Corporation PLC's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Amarin Corporation PLC is 8.63, ranking 33 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.53, which is -51.83% below the recent high of -1.70 and -8681.19% above the recent low of -309.99.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 112/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Amarin Corporation PLC is 5.00, ranking 352 out of 392 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 12.00 and a low of 12.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Hold
Current Rating
12.000
Target Price
-14.83%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
Amarin Corporation PLC
AMRN
2
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Intellia Therapeutics Inc
NTLA
24
Beigene Ltd
ONC
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Amarin Corporation PLC is 6.39, ranking 256 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 16.69 and the support level at 13.43, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
14.697
Buy
MA10
15.014
Sell
MA20
15.247
Sell
MA50
14.854
Sell
MA100
16.017
Sell
MA200
14.936
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Amarin Corporation PLC is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 22.49%, representing a quarter-over-quarter decrease of 6.77%. The largest institutional shareholder is PRFDX, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Amarin Corporation PLC is 4.45, ranking 85 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.86. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Amarin Corporation PLC’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
Score
Beta vs S&P 500 index
0.86
VaR
+5.57%
240-Day Maximum Drawdown
+33.33%
240-Day Volatility
+74.63%
Return
Best Daily Return
60 days
+16.89%
120 days
+16.89%
5 years
+32.87%
Worst Daily Return
60 days
-9.79%
120 days
-11.25%
5 years
-43.07%
Sharpe Ratio
60 days
-0.52
120 days
+0.00
5 years
-0.23
Risk Assessment
Maximum Drawdown
240 days
+33.33%
3 years
+74.02%
5 years
+93.15%
Return-to-Drawdown Ratio
240 days
+0.85
3 years
-0.23
5 years
-0.18
Skewness
240 days
+1.57
3 years
+0.90
5 years
-0.11
Volatility
Realised Volatility
240 days
+74.63%
5 years
+74.98%
Standardised True Range
240 days
+5.29%
5 years
+12.56%
Downside Risk-Adjusted Return
120 days
+0.29%
240 days
+0.29%
Maximum Daily Upside Volatility
60 days
+41.88%
Maximum Daily Downside Volatility
60 days
+33.06%
Liquidity
Average Turnover Rate
60 days
+0.54%
120 days
+2.66%
5 years
--
Turnover Deviation
20 days
-95.06%
60 days
-91.51%
120 days
-58.32%
Peer Comparison
Biotechnology & Medical Research
Amarin Corporation PLC
AMRN
6.49 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
